Ensign Peak Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.05M | Hold |
48,160
| – | – | ﹤0.01% | 1223 |
|
|
2025
Q1 | $1.17M | Hold |
48,160
| – | – | ﹤0.01% | 1167 |
|
|
2024
Q4 | $1.01M | Hold |
48,160
| – | – | ﹤0.01% | 1314 |
|
|
2024
Q3 | $957K | Hold |
48,160
| – | – | ﹤0.01% | 1345 |
|
|
2024
Q2 | $746K | Hold |
48,160
| – | – | ﹤0.01% | 1458 |
|
|
2024
Q1 | $768K | Sell |
48,160
-2,430
| -5% | -$38.7K | ﹤0.01% | 1484 |
|
|
2023
Q4 | $850K | Hold |
50,590
| – | – | ﹤0.01% | 1472 |
|
|
2023
Q3 | $591K | Hold |
50,590
| – | – | ﹤0.01% | 1540 |
|
|
2023
Q2 | $680K | Hold |
50,590
| – | – | ﹤0.01% | 1520 |
|
|
2023
Q1 | $839K | Hold |
50,590
| – | – | ﹤0.01% | 1391 |
|
|
2022
Q4 | $941K | Buy |
50,590
+25,350
| +100% | +$472K | ﹤0.01% | 1211 |
|
|
2022
Q3 | $324K | Buy |
25,240
+23,820
| +1,677% | +$306K | ﹤0.01% | 1672 |
|
|
2022
Q2 | $10K | Buy |
+1,420
| New | +$10K | ﹤0.01% | 2144 |
|